Literature DB >> 15231735

Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome.

Michael N Corradetti1, Ken Inoki, Nabeel Bardeesy, Ronald A DePinho, Kun-Liang Guan.   

Abstract

Tuberous sclerosis complex (TSC) and Peutz-Jeghers syndrome (PJS) are dominantly inherited benign tumor syndromes that share striking histopathological similarities. Here we show that LKB1, the gene mutated in PJS, acts as a tumor suppressor by activating TSC2, the gene mutated in TSC. Like TSC2, LKB1 inhibits the phosphorylation of the key translational regulators S6K and 4EBP1. Furthermore, we show that LKB1 activates TSC2 through the AMP-dependent protein kinase (AMPK), indicating that LKB1 plays a role in cell growth regulation in response to cellular energy levels. Our results suggest that PJS and other benign tumor syndromes could be caused by dysregulation of the TSC2/mTOR pathway.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15231735      PMCID: PMC443516          DOI: 10.1101/gad.1199104

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  28 in total

Review 1.  AMP-activated protein kinase: the energy charge hypothesis revisited.

Authors:  D G Hardie; S A Hawley
Journal:  Bioessays       Date:  2001-12       Impact factor: 4.345

2.  Colonic hamartomas in tuberous sclerosis.

Authors:  G Devroede; B Lemieux; S Massé; J Lamarche; P S Herman
Journal:  Gastroenterology       Date:  1988-01       Impact factor: 22.682

3.  Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway.

Authors:  Caroline Treins; Sophie Giorgetti-Peraldi; Joseph Murdaca; Gregg L Semenza; Emmanuel Van Obberghen
Journal:  J Biol Chem       Date:  2002-05-24       Impact factor: 5.157

4.  Mammalian TOR: a homeostatic ATP sensor.

Authors:  P B Dennis; A Jaeschke; M Saitoh; B Fowler; S C Kozma; G Thomas
Journal:  Science       Date:  2001-11-02       Impact factor: 47.728

5.  Vascular abnormalities and deregulation of VEGF in Lkb1-deficient mice.

Authors:  A Ylikorkala; D J Rossi; N Korsisaari; K Luukko; K Alitalo; M Henkemeyer; T P Mäkelä
Journal:  Science       Date:  2001-08-17       Impact factor: 47.728

6.  A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells.

Authors:  David J Kwiatkowski; Hongbing Zhang; Jennifer L Bandura; Kristina M Heiberger; Michael Glogauer; Nisreen el-Hashemite; Hiroaki Onda
Journal:  Hum Mol Genet       Date:  2002-03-01       Impact factor: 6.150

7.  Role of AMP-activated protein kinase in mechanism of metformin action.

Authors:  G Zhou; R Myers; Y Li; Y Chen; X Shen; J Fenyk-Melody; M Wu; J Ventre; T Doebber; N Fujii; N Musi; M F Hirshman; L J Goodyear; D E Moller
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

Review 8.  The genetic basis of tuberous sclerosis.

Authors:  J Young; S Povey
Journal:  Mol Med Today       Date:  1998-07

9.  Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway.

Authors:  Brendan D Manning; Andrew R Tee; M Nicole Logsdon; John Blenis; Lewis C Cantley
Journal:  Mol Cell       Date:  2002-07       Impact factor: 17.970

10.  Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade.

Authors:  Simon A Hawley; Jérôme Boudeau; Jennifer L Reid; Kirsty J Mustard; Lina Udd; Tomi P Mäkelä; Dario R Alessi; D Grahame Hardie
Journal:  J Biol       Date:  2003-09-24
View more
  207 in total

1.  AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress.

Authors:  Sang-Min Jeon; Navdeep S Chandel; Nissim Hay
Journal:  Nature       Date:  2012-05-09       Impact factor: 49.962

2.  Dynamic Lkb1-TORC1 signaling as a possible mechanism for regulating the endoderm-intestine transition.

Authors:  Kathryn E Marshall; Amber J Tomasini; Khadijah Makky; Suresh N Kumar; Alan N Mayer
Journal:  Dev Dyn       Date:  2010-11       Impact factor: 3.780

3.  Liver kinase B1 (LKB1) in the pathogenesis of UVB-induced murine basal cell carcinoma.

Authors:  Yevgeniya A Byekova; Jennifer L Herrmann; Jianmin Xu; Craig A Elmets; Mohammad Athar
Journal:  Arch Biochem Biophys       Date:  2011-01-25       Impact factor: 4.013

Review 4.  The role of LKB1 in lung cancer.

Authors:  Montse Sanchez-Cespedes
Journal:  Fam Cancer       Date:  2011-09       Impact factor: 2.375

Review 5.  MenTORing Immunity: mTOR Signaling in the Development and Function of Tissue-Resident Immune Cells.

Authors:  Russell G Jones; Edward J Pearce
Journal:  Immunity       Date:  2017-05-16       Impact factor: 31.745

6.  Curcumin disrupts the Mammalian target of rapamycin-raptor complex.

Authors:  Christopher S Beevers; Long Chen; Lei Liu; Yan Luo; Nicholas J G Webster; Shile Huang
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

Review 7.  PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.

Authors:  Vera P Krymskaya; Elena A Goncharova
Journal:  Cell Cycle       Date:  2009-02-06       Impact factor: 4.534

8.  Inhibition of protein synthesis by Y box-binding protein 1 blocks oncogenic cell transformation.

Authors:  Andreas G Bader; Peter K Vogt
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

9.  Two novel STK11 missense mutations induce phosphorylation of S6K and promote cell proliferation in Peutz-Jeghers syndrome.

Authors:  Ran Li; Zhiqing Wang; Shu Liu; Baoping Wu; Di Zeng; Yali Zhang; Lanbo Gong; Feihong Deng; Haoxuan Zheng; Yadong Wang; Chudi Chen; Junsheng Chen; Bo Jiang
Journal:  Oncol Lett       Date:  2017-11-17       Impact factor: 2.967

10.  Why is an energy metabolic defect the common outcome in BMFS?

Authors:  Paolo Degan; Silvia Ravera; Enrico Cappelli
Journal:  Cell Cycle       Date:  2016-08-11       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.